SynthesisFrontiers in medicine2025
Dexmedetomidine reduces the inflammation level and morality in adult sepsis: a systemic review and meta-analysis based on randomized controlled trials.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeting the gut to heal the skin: probiotic supplementation reduces wound infection risk and clinical burden in critically ill patients-a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Sedation as an Immunomodulator of Inflammatory Responses in the Lung-Brain Axis of ARDS.International journal of molecular sciences · 2026Review
- Comparison of dexmedetomidine, haloperidol, and propofol sedation on intra-abdominal pressure, inflammatory response, and clinical outcomes in patients with abdominal sepsis: A randomised controlled study.Indian journal of anaesthesia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is a systemic inflammatory response syndrome characterized by an inflammatory cytokine storm and immune dysregulation. The clinical benefits of dexmedetomidine in patients with sepsis remain unclear. This study aimed to explore the effects of dexmedetomidine on the inflammatory status and clinical outcomes of patients with sepsis. Methods: This study searched PubMed, Embase, and the Cochrane Library for records from the setup day of each database up to August 1, 2025. The search strategy was as follows: (Dexmedetomidine OR Dexmedetomidine Hydrochloride OR Precedex OR Igami) AND (Sepsis OR Bloodstream Infection OR Bloodstream Infections OR Septicemia OR Septicemias). The primary outcomes included interleukin-6 (IL-6), tumor necrosis factor- Results: A total of 1,550 sepsis patients were included in this study, among whom 759 received dexmedetomidine treatment. Regarding inflammatory factors, the analysis results showed that dexmedetomidine significantly reduced interleukin-6 (IL-6) [standardized mean difference (SMD) = 0.04, 95% confidence interval (95%CI) = (-0.11, 0.19), Conclusion: Dexmedetomidine can reduce the levels of IL-6 and TNF-αin patients with sepsis, while also decreasing in-hospital mortality and 28-day mortality. Furthermore, early identification of sepsis and subsequent administration of dexmedetomidine for sedation and anti-inflammatory therapy may yield more pronounced clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.